Top

Published in:

Open Access 01-05-2019 | Cervical Cancer | Original Article

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

Authors: Dr. Nina Poetsch, Dr. Alina Sturdza, PD Dr. Stefanie Aust, Phd, Assoc.-Prof. PD Dr. Stephan Polterauer, Assoc.-Prof. PD Dr. Christoph Grimm, Dr. Richard Schwameis, Phd, Univ.-Prof. Dr. Richard Pötter, Univ.-Prof. Dr. Heinz Koelbl, Univ.-Prof. Dr. Alexander Reinthaller, Assoc.-Prof. PD Dr. Veronika Seebacher, MD

Published in: Strahlentherapie und Onkologie | Issue 5/2019

Abstract

Background

Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present study was to investigate the value of pretreatment serum BChE levels as a prognostic biomarker in patients with cervical cancer treated with primary (chemotherapy-[chemo-])radiation therapy.

Methods

We retrospectively evaluated data of a consecutive series of patients with cervical cancer treated with primary (chemo-)radiation therapy between 1998 and 2015. Pretreatment serum BChE levels were correlated with clinico-pathological parameters and response to treatment. Uni- and multivariate survival analyses were performed to assess the association between decreased serum BChE levels and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).

Results

A total of 356 patients were eligible for inclusion into the present study. The median (IQR) pretreatment serum BChE level was 6180 (4990–7710) IU/l. Lower serum BChE levels were associated with lower BMI (p < 0.001), advanced tumor stage (p = 0.04), poor treatment response (p = 0.002), the occurrence of disease recurrence (p = 0.003), and the risk of death (p < 0.001). In uni- and multivariate analyses, low pretreatment serum BChE levels were independently associated with shorter PFS (HR 1.8 [1.2–2.6]; p = 0.002), CSS (HR 2.2 [1.4–3.5], p < 0.001), and OS (HR 2.0 [1.4–2.9]; p < 0.001).

Conclusions

Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.

Sankaranarayanan R, Nene BM, Shastri SS et al (2009) HPV screening for cervical cancer in rural India. N Engl J Med 360:1385–1394. https://doi.org/10.1056/NEJMoa0808516 CrossRefPubMed

Collaboration C for cervical cancer meta-analysis (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–5812. https://doi.org/10.1200/JCO.2008.16.4368 CrossRef

Pearcey R, Brundage M, Drouin P et al (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972. https://doi.org/10.1200/JCO.2002.20.4.966 CrossRefPubMed

Marnitz S, Schram J, Budach V et al (2015) Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy. Strahlenther Onkol 191:421–428. https://doi.org/10.1007/s00066-014-0785-z CrossRefPubMed

Uk SL, Ae YK, Young-Ho Y et al (2017) General health status of long-term cervical cancer survivors after radiotherapy. Strahlenther Onkol 193:543–551. https://doi.org/10.1007/s00066-017-1143-8 CrossRef

Hass P, Eggemann H, Costa SD, Ignatov A (2017) Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. Strahlenther Onkol 193:1048–1055. https://doi.org/10.1007/s00066-017-1174-1 CrossRefPubMed

Polterauer S, Grimm C, Hofstetter G et al (2012) Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer 107:918–924. https://doi.org/10.1038/bjc.2012.340 CrossRefPubMedPubMedCentral

Rose PG, Java J, Whitney CW et al (2015) Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized trials of Chemoradiotherapy. J Clin Oncol 33:2136–2142. https://doi.org/10.1200/JCO.2014.57.7122 CrossRefPubMedPubMedCentral

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentral

10.

Gkika E, Bettinger D, Krafft L et al (2018) The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 194:403–413. https://doi.org/10.1007/s00066-017-1256-0 CrossRefPubMed

11.

Argilés JM, Busquets S, Stemmler B, López-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14:754–762. https://doi.org/10.1038/nrc3829 CrossRefPubMed

12.

Polterauer S, Grimm C, Tempfer C et al (2007) C‑reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 107:114–117. https://doi.org/10.1016/j.ygyno.2007.06.001 CrossRefPubMed

13.

Zheng R‑R, Huang M, Jin C et al (2016) Cervical cancer systemic inflammation score: a novel predictor of prognosis. Oncotarget 7:15230–15242. https://doi.org/10.18632/oncotarget.7378 CrossRefPubMedPubMedCentral

14.

Wu J, Chen M, Liang C, Su W (2017) Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget 8:13400–13412. https://doi.org/10.18632/oncotarget.14541 CrossRefPubMedPubMedCentral

15.

Cheng J, Zeng Z, Ye Q et al (2017) The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis. Oncotarget 8. https://doi.org/10.18632/oncotarget.15358 CrossRefPubMedPubMedCentral

16.

Xiao Y, Ren Y‑K, Cheng H‑J et al (2015) Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy. Int J Clin Exp Pathol 8:5273–5281PubMedPubMedCentral

17.

Escande A, Haie-Meder C, Maroun P et al (2016) Neutrophilia in locally advanced cervical cancer: a novel biomarker for image-guided adaptive brachytherapy? Oncotarget 7:74886–74894. https://doi.org/10.18632/oncotarget.12440 CrossRefPubMedPubMedCentral

18.

Soliday FK, Conley YP, Henker R (2010) Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. AANA J 78:313–320PubMed

19.

Cucuianu M, Nistor T, Hâncu N et al (2002) Serum cholinesterase activity correlates with serum insulin, C‑peptide and free fatty acids levels in patients with type 2 diabetes. Rom J Intern Med 40:43–51PubMed

20.

Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC (2012) Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 11:356–363CrossRefPubMed

21.

Gu S‑Z, Zhao X‑H, Quan P et al (2005) Alterations of serum cholinesterase in patients with gastric cancer. World J Gastroenterol 11:4604–4606CrossRefPubMedPubMedCentral

22.

Koie T, Ohyama C, Mikami J et al (2014) Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy. ScientificWorldJournal 2014:948305. https://doi.org/10.1155/2014/948305 CrossRefPubMedPubMedCentral

23.

Zhang B, Shen C, Jin J et al (2016) Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma. Int Urol Nephrol 48:1993–1999. https://doi.org/10.1007/s11255-016-1401-1 CrossRefPubMed

24.

Koie T, Ohyama C, Hatakeyama S et al (2016) Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy. Int J Clin Oncol 21:379–383. https://doi.org/10.1007/s10147-015-0880-x CrossRefPubMed

25.

Chougule A, Hussain S, Agarwal DP (2008) Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther 4:21–25CrossRefPubMed

26.

Prabhu K, Naik D, Ray S et al (2011) Significance of serum butyrylcholinesterase levels in oral cancer. Australas Med J 4:374–378. https://doi.org/10.4066/AMJ.2011.569 CrossRefPubMedPubMedCentral

27.

Bradamante V, Smigovec E, Buković D et al (2000) Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy. Coll Antropol 24:373–380PubMed

28.

Creasman WT (1995) New gynecologic cancer staging. Gynecol Oncol 58:157–158. https://doi.org/10.1006/gyno.1995.1203 CrossRefPubMed

29.

Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107–108. https://doi.org/10.1016/j.ijgo.2009.02.009 CrossRefPubMed

30.

Pötter R, Georg P, Dimopoulos JCA et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123. https://doi.org/10.1016/j.radonc.2011.07.012 CrossRefPubMedPubMedCentral

31.

Pötter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155. https://doi.org/10.1016/j.radonc.2007.04.012 CrossRefPubMed

32.

Sturdza A, Pötter R, Fokdal LU et al (2016) Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120:428–433. https://doi.org/10.1016/j.radonc.2016.03.011 CrossRefPubMed

33.

Pavo N, Raderer M, Goliasch G et al (2017) Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. Oncotarget 8:81250–81260. https://doi.org/10.18632/oncotarget.17131 CrossRefPubMedPubMedCentral

34.

Santarpia L, Alfonsi L, Pasanisi F et al (2006) Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition 22:355–360. https://doi.org/10.1016/j.nut.2005.06.011 CrossRefPubMed

35.

Delgado G, Bundy B, Zaino R et al (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38:352–357. https://doi.org/10.1016/0090-8258(90)90072-S CrossRefPubMed

36.

Polterauer S, Grimm C, Seebacher V et al (2010) The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer 20:1052–1057. https://doi.org/10.1111/IGC.0b013e3181e64bb1 CrossRefPubMed

37.

Fuhrman MP, Charney P, Mueller CM (2004) Hepatic proteins and nutrition assessment. J Am Diet Assoc 104:1258–1264. https://doi.org/10.1016/j.jada.2004.05.213 CrossRefPubMed

38.

Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW (2008) Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol 64:895–900. https://doi.org/10.1007/s00228-008-0499-1 CrossRefPubMed

39.

Duysen EG, Li B, Darvesh S, Lockridge O (2007) Sensitivity of butyrylcholinesterase knockout mice to (‑-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer’s disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 233:60–69. https://doi.org/10.1016/j.tox.2006.11.069 CrossRefPubMed

40.

Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154:1558–1571. https://doi.org/10.1038/bjp.2008.185 CrossRefPubMedPubMedCentral

41.

Song P, Sekhon HS, Proskocil B et al (2003) Synthesis of acetylcholine by lung cancer. Life Sci 72:2159–2168CrossRefPubMed

42.

Calleja-Macias IE, Kalantari M, Bernard H‑U (2009) Cholinergic signaling through nicotinic acetylcholine receptors stimulates the proliferation of cervical cancer cells: an explanation for the molecular role of tobacco smoking in cervical carcinogenesis? Int J Cancer 124:1090–1096. https://doi.org/10.1002/ijc.24053 CrossRefPubMed

43.

Davis L, Britten JJ, Morgan M (1997) Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 52:244–260CrossRefPubMed

Title: The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy
Authors: Dr. Nina Poetsch
Dr. Alina Sturdza
PD Dr. Stefanie Aust, Phd
Assoc.-Prof. PD Dr. Stephan Polterauer
Assoc.-Prof. PD Dr. Christoph Grimm
Dr. Richard Schwameis, Phd
Univ.-Prof. Dr. Richard Pötter
Univ.-Prof. Dr. Heinz Koelbl
Univ.-Prof. Dr. Alexander Reinthaller
Assoc.-Prof. PD Dr. Veronika Seebacher, MD
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keywords: Cervical Cancer
Cervical Cancer
Radiotherapy
Cytostatic Therapy
Biomarkers
Published in: Strahlentherapie und Onkologie / Issue 5/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01430-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Einfluss der prophylaktischen Ganzhirnbestrahlung auf das Gesamtüberleben von Patienten mit einem fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom

Endokrine Funktionsstörungen nach Bestrahlung von Hirntumoren bei Kindern und jungen Erwachsenen

Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer

Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer

Chemoradiotherapy for anal cancer: are we as good as we think?

Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer